Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 7/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 7/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 7/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709928 | 0.87 | KCNMA1 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1MDM4 | |
| SCHEMBL6707129 | 0.85 | KMT2A (0.53) | KCNQ3KCNQ2KCNE1KCNQ1MDM4 | |
| SCHEMBL6708189 | 0.84 | NPC1 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1MDM4 | |
| SCHEMBL6710007 | 0.83 | HCAR3 (0.50) | MDM4TP53MDM2HTTKDR | |
| SCHEMBL6706188 | 0.83 | KCNMA1 (0.57) | MDM4TP53MDM2HTTKDR | |
| SCHEMBL6707105 | 0.82 | MAPT (0.51) | KCNQ3KCNQ2MDM4TP53MDM2 | |
| SCHEMBL6707243 | 0.82 | GAA (0.61) | MDM4TP53MDM2RAB9ASMN1; SMN2 | |
| SCHEMBL6705957 | 0.81 | KCNMA1 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1MDM4 | |
| SCHEMBL6705924 | 0.81 | PHGDH (0.69) | MDM4TP53MDM2HTTKDR | |
| SCHEMBL6705919 | 0.79 | KMT2A (0.62) | KCNQ3KCNQ2KCNE1KCNQ1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794397-B2 | ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2004-09-21 | — | — | US | claimed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | claimed |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | CYTOVIA, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794397-B2 | ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, BAD, CASP12 | KCNQ3 3841/4885KCNQ2 3402/4885KCNE1 1801/4885 |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | NAMPT, BAD, NNT | KCNQ3 3677/4885KCNQ2 3538/4885KCNE1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.